Summary & Overview
HCPCS Q5148: Filgrastim‑txid (Nypozi) biosimilar injection, 1 microgram
HCPCS Level II code Q5148 designates the injectable biosimilar filgrastim‑txid (Nypozi) in a 1 microgram unit. As a biosimilar to filgrastim, this agent is used for hematopoietic support to reduce the duration of neutropenia after myelosuppressive chemotherapy and in other indications requiring granulocyte colony‑stimulating factor therapy. Nationally, biosimilar filgrastim codes matter for cost, access, and formulary placement across public and commercial payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The overview outlines payer coverage considerations and common administrative practices used when billing for biosimilar filgrastim injections.
Readers will learn: clinical context for use of Q5148; typical sites of service and service type for billing; which payers are commonly involved; the typical modifier set used for injectable drug administration (listed elsewhere); and where input data is unavailable. The publication provides benchmarks and policy updates relevant to biosimilar adoption, billing guidance, and clinical implications for supportive oncology care. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q5148 represents the injection of filgrastim‑txid (Nypozi), a biosimilar formulation of filgrastim, dosed per 1 microgram unit. This code denotes a biologic supportive-care medication used to stimulate neutrophil recovery, commonly administered to reduce the duration of neutropenia in patients receiving myelosuppressive chemotherapy.
Service type: Drug administration — injectable biosimilar therapy
Typical site of service: Outpatient infusion/oncology clinic, hospital outpatient department, or specialty pharmacy administration setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with chemotherapy-induced neutropenia receives supportive care in an outpatient oncology infusion clinic. The prescribing oncologist orders a single-dose subcutaneous injection of filgrastim‑txid (Nypozi) to stimulate neutrophil recovery after myelosuppressive chemotherapy. The clinic nurse verifies the medication order, confirms allergy and weight-based dosing, prepares the syringe using aseptic technique, documents lot number and expiration, and administers the injection subcutaneously in the abdomen or thigh. Observation for immediate adverse reaction follows for 15–30 minutes, vital signs and injection site are documented, and the encounter is billed using HCPCS Level II code Q5148 with appropriate modifier(s) to reflect service circumstances (for example, physician-assigned institutional or payer-required modifiers). Typical sites of service are outpatient infusion centers, physician offices, or hospital outpatient departments. The clinical workflow includes order entry, nursing assessment, medication preparation, administration, documentation of lot and dose, patient education on self‑administration if discharged with additional doses, and scheduling of follow‑up labs to monitor absolute neutrophil count (ANC).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When any portion of a single‑use vial or syringe of filgrastim‑txid is discarded and documentation supports wastage. |